Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers

Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers

Estimates the probabilities of optimal and nonoptimal treatment decisions if infliximab or adalimumab drug trough level (DL) and anti-drug antibodies (ADAbs) are tested or not in rheumatoid arthritis, and models cost-effectiveness of performing such monitoring on a routine basis. Source: National Li...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biologics 2016-04, Vol.10 (Issue 1), p.67-73
1. Verfasser: Laine, Juha
Format: Artikel
Sprache:eng
Schlagworte:
anti-drug antibodies
Anti-immunoglobulin autoantibodies
Biological products
Clinical medicine
Cost analysis
Cost effectiveness
Decision making
drug concentration
Drug dosages
Drug monitoring
Economic impact
Immunoglobulins
Infliximab
Laboratories
Monoclonal antibodies
Original Research
Patients
Rheumatoid arthritis
Rheumatology
Studies
Substance abuse treatment
Systematic review
TNF inhibitors
TNF blockers
Treatment
Tumor necrosis factor-TNF
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Estimates the probabilities of optimal and nonoptimal treatment decisions if infliximab or adalimumab drug trough level (DL) and anti-drug antibodies (ADAbs) are tested or not in rheumatoid arthritis, and models cost-effectiveness of performing such monitoring on a routine basis. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.
ISSN:1177-5475
1177-5491
1177-5491
DOI:10.2147/BTT.S96982